BYNDER
23.1.2024 13:45:26 CET | Business Wire | Press release
Bynder, a global leader in enterprise digital asset management (DAM) has today released data highlighting the strategic importance of enterprise DAM and content for brands looking to grow amidst market uncertainty and economic headwinds.
- Increased market demand highlighted by record number of new business logos and customer expansion in Q4 2023 as brands continue to see content as a strategic enabler
- AI functionality drives demand and is included in nearly 50% of new business deals in Q4
- Customers report time savings of 30-40% utilizing AI, and are 2x more likely to find the assets they need
- Leading indicators show significant growth in enterprise DAM usage and integration as businesses look to improve efficiency and drive increased ROI from their investments in content.
The need to deliver customers an exceptional content experience is driving more brands to look for efficiency, speed to value and increased ROI in the creation, management and distribution of content. In this landscape an enterprise DAM platform becomes mission critical as organizations compete for share of wallet in a growing and increasingly crowded digital and retail marketplace.
Recent AI innovations have highlighted Bynder’s market leadership, and its host of AI and automation capabilities have led to continued growth in new business, customer adoption and platform usage. The latest of these innovations, AI Search Experience, enables identification of similar assets and text in images, as well as the ability to search using images and identify duplicate assets. These capabilities allow teams to find, reuse and deliver more relevant content, quicker and more effectively.
Brittany Chase, Project Specialist at Architecture and Planning firm, HFA, said, “AI Search Experience would save between 30% and 40% of time from not having to upload and tag assets that already exist in the DAM.” In addition, a US-based healthcare company attributed a minimum saving of 6 hours a week to the new AI functionality, enabling team members to focus on more strategic initiatives.
As organizations continue to use content as a strategic advantage, usage of enterprise DAM enables efficiency across the entire content lifecycle. Across 2023, Bynder saw a 38% year-on-year growth in the number of assets stored on their platform, and a 250% increase in delivery of assets from Bynder’s platform to websites. Over the holiday season Bynder saw an exponential uplift in assets created, stored and distributed as brands looked to deliver exceptional digital shopping experiences.
Bynder’s hosts the largest marketplace of out of the box integrations and in 2023 this grew 38%. In addition, Bynder reported a 176% increase in API calls to their platform showing the criticality of a connected ecosystem to improve content operations.
Bynder CEO Bob Hickey said, “As digital commerce continues to accelerate, brands need to provide a seamless content experience to their customers. Our continued year-on-year growth, culminating in a record Q4 in 2023, indicates that investment in an enterprise DAM platform is vital for those looking to deliver content experiences while gaining compelling value and ROI from their content operations and IT investments.
“We’re pleased to see that our ongoing innovation and market leadership in AI has further driven our growth in Q4, highlighting that AI has become a strategic tool for marketers looking to streamline content operations and improve customer experience.”
For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123344937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
